Skip to main content

Crescent Biopharma, Inc Investor Event Transcript, Nov 18, 2026

Crescent Biopharma, Inc. (CBIO)

Crescent Biopharma said three of its programs are now dosing patients in the clinic, and it has cleared nine INDs with partner Colune Biotech this year. It expects over 2,000 patients dosed across its portfolio by the middle of next year, and plans to start the first of multiple Phase III studies by early 2028. AI summary

Investor Event Transcript 2026-11-18 For: 2026-12-31
Added on November 18, 2026

Conference Transcript - CBIO 2026-11-18

Josh Brown, CEO

All right, show.

Albert Jams, Analyst — Associate, Jefferies

Good afternoon, everyone, and thank you for joining us at Jeffrey's Linden Healthcare Conference. My name is Albert Jams, associate on Akash Tawari's team. Akash is currently running between meetings and should be joining us shortly. In the meantime, it's my pleasure to welcome the team from Crescent Biopharma, Joshua Brom, CEO, and Jonathan McNeil, president and COO. Before we jump into Q&A, I will turn it over to Joshua and Jonathan for a few opening remarks.

Josh Brown, CEO

Great. Thanks, Albert. Thanks, Jeffries, for the invitation to be here. We will make some forward-looking statements today, so please refer to RCC filings for those matters or questions. Look, it's great to be here as we head into wrapping up 2026 and looking forward to 2027. 2026 has been an exceptional year for the company. We have three programs we brought into clinic this year, all now dosing patients, and we can talk more about some of the milestones associated with those. We have cleared nine INDs between ourselves and Colune Biotech, our partner, over the course of this year, And we really are executing on our global strategy to deliver on combination therapies for patients that are living with oncology. We have built a dual kind of pillar of strategy between the next-gen IO backbone with the PD-1 VEGF bispecific that we're developing, CR001, as well as our own ADC portfolio, which we have CR002, which is our PD-L1 topo ADC, and CR003, which is our integrated beta-6 topo ADC as well, all in the clinic. So we have a slew of data coming next year. I'm sure we'll get into more of that, but we're well set up to deliver for patients and execute on our global strategy.

Albert Jams, Analyst — Associate, Jefferies

Thanks, Joshua. Maybe to kick things off, I wanted to start with Harmony 3 and what the upcoming readout could mean for the broader PD-1 VEGF class. What would you define as a win for Harmony 3 and final PIS and interim OS readout, and which parts of the data set matter the most for the PD for the whole class, and maybe beyond the headline header ratios?

Jonathan McNeill, COO

Yeah, thank you. So, as we look at the broader class, since ASCO and ESMO, there's been quite a few positive updates around ivanesimab and the broader PD-1-VEGF class. So, as you know, there's been multiple positive Phase III trials with ivanesimab, and so as we look toward Harmony III, we would define success as results consistent with those prior trials. So, what that means is a PFS ratio that supports the success toward OS. But from our perspective, whether that is statistically significant or not at the interim OS versus the more final OS is less important than a result that is consistent with what we've previously seen. Because if Ivanesimab behaves in a way in Harmony 3 like it has in the prior trials, then our strategy of developing our own PD-1 VEGF, our ADC portfolio, and combinations will remain unchanged, and we'll continue to drive toward the multiple data sets in 2027.

Josh Brown, CEO

Yeah, I think there's obviously learnings that we may take away from study design, powering stats of that study, like we've looked at the previous studies that both Akiso and Summit have run. But I do think that at this point, the class itself has been completely validated. This is a new class of drugs. Second gen IO backbone therapy is going to be driven by the bispecifics. I think pharma's already there. I've seen a big shift from pharma's mentality kind of pre-ASCO, pre-Harmony 6 data, to where we are. Today, and, you know, people kind of being on the fence now, everyone's trying to figure out the play for their own second, you know, next-gen I.O. backbone. I think that, you know, Jonathan's well-spoken. We won't change our strategy here. I think there's a specific question that Summit will need to answer. Summit's done a wonderful job of exploring this next-gen I.O. backbone, the monotherapy data they put together, the studies they've run, the money they've spent to do that has been great. I do think that there's some real advantages This is being a very fast follower and learnings from the success that they've had. And I do think that's going to serve us well as we have now become a leader amongst those that are developing a next-gen I.O. backbone.

Akash Tawari, Analyst — Jefferies

I'm sorry about that. I think, can we bridge that unless Albert already asked? We got the CRL from Harmony. What were the biggest takeaways that you're going to be applying to your development program? From that.

Josh Brown, CEO

Yeah, look, I think a couple things. One is the FDA means what they say when you agree to them up front about what they want you to do, right? And so I think have those conversations, be clear about what you agree to, and then make sure that you, you know, pull your endpoints and you run your study in a way that will deliver you the outcome you need to deliver on what you've agreed to at the FDA. I think they were clear about that. I think that the other part of that is they were pretty clear about 93% of events came from China patients. I think that they didn't love that, right, so they called that out. And they also talked about rerunning a study or running a different study that showed the outcomes that they wanted to see and agree to, but they also called out that that endpoint could be OS, PFS, or other endpoints. And so I think that also shows the FDA's willingness to be open in discussion around what endpoints are on the table. So we will take advantage of that in our discussions with regulators, including the FDA. And so I think that's a positive that's taken away from that. And I think there's no read-through to the class here. This is about the FDA just saying, hey, look, we agreed on an outcome with you guys. You guys didn't hit it, so we're not going to let you go forward. But if you do rerun the study or run a different study, make sure that you have endpoints we've agreed to, And we're not just stuck on OS with PFSs available or other endpoints, but let's agree on those up front.

Akash Tawari, Analyst — Jefferies

Understood. I think your point is super important. It's not just sometimes how many patients from certain geographies you're enrolling. It's actually how many of said patients are actually contributing to absolute events. And I think that's a point really well taken. But also, you know, we've talked about this before, I don't sense with your team that you feel like there isn't an ability to get an OS benefit with this class of drugs. So there's an accelerated path to approval. But I'd love to get your take on that as well. Because again, I look at Mariposa too, I look at the absolute delta, it's, I didn't necessarily see a difference in the absolute improvement. How confident is your team that, you know, from a well-powered trial that takes into account some of the learnings you've learned from the space, that you would be able to deliver, not just on a PFS benefit, but really on an OS benefit in that second-line population?

Jonathan McNeill, COO

Well. I won't speak to the second-line population specifically, but I think more broadly, just because it is a relatively smaller opportunity, but what we've seen is that the class, and Ivanesimab in particular, has delivered OS benefits that have been statistically significant in Asian patient populations, and even in this trial with later OS reads in Western populations as well. And so from our perspective, our confidence in the class, our confidence in ability to deliver both as monotherapy and in combination with chemotherapy, like we saw in the recent BTC results from McKeso, is not changed by this complete response letter or the emerging data. Of course, we'll continue to monitor the space, but our focus on generating data with our own assets across standard care chemo combinations and ADC combinations remains, and we remain very confident in the ability to generate data that's meaningful for patients, but from a PFS and an OS benefit.

Josh Brown, CEO

Yeah, and look, I'd say, like, you know, if you think about the first iteration of this movie when the PD-1 first gen were being developed, you go back and look at history, which is a good lesson for us to remind ourselves of, all of those phase three studies weren't positive, right? You had Optivo in the lead, Keytruda came from behind, took $30 billion of the market share, and, you know, here we are now, second gen, we're watching the second movie play out, and the first four studies are positive, right? So I think, you know, we're in a good spot here, and I think, you know, again, credit to Summit for having to manage through the Chinese patient population, you know, kind of shoehorning in different patient populations and the timing of that data when that data's mature. So I think an advantage for us is that we're starting with Western and global patients, and we can design the study with all of those lessons learned. We await for the data to be mature, be careful about what we agree to with the FDA and get alignment ahead of time, and likely increase our chances of having a positive outcome in the study. And I think the fact that we've seen four already be positive across different indications, not just lung but not BTC, I think it's highly likely we can design a study that will be powered to have a good outcome.

Akash Tawari, Analyst — Jefferies

A little angle on this, which is, you know, kind of quite interesting. You know, you talk to companies who are making T-cell engagers or ADCs, and they're often, they'll often tell you, like, look, there might be the right time and place to add different medications. So it's not just combination, but it's really sequencing them as well. Right? Maybe you debulk with an ADC, you have a T-cell engager for really that kind of survival tail benefit. I would argue you guys have a unique advantage with a partner with Kulun, where A, a lot of people have chemo. Not a lot of people have SAC-TMT. There's two companies that do, you and Merck. And then number two, in China, my sense is you can probably explore optimal dose, spacing out dosing, induction, maintenance, you know, kind of formats in a way that I don't think everyone else would necessarily have access to. So, can you comment a bit how much you're really thinking about, again, A, using SAC-DMT. Competitive advantage to really explore PD-1 VEGF biology. And then number two, alternative dosing formats that could allow you to really develop a differentiated data set here.

Josh Brown, CEO

Yeah, I'll just start with the Colune partnership and how valuable that is to us. And then Jonathan, maybe talk about SAC TMT and some of the other things we're thinking about. But I will say that, you know, look, this is really two companies coming together that are very much like-minded, both from an execution commitment and excellence, and also from A belief in combination therapy, and that's where this is going for the space. So I think I've said this a couple of times now publicly, but I think Colune's going to give a blueprint on how to use the next-gen bi-specific IO therapy and oncology. In our last earnings release, we said we have now cleared nine INDs. That's up two INDs from what we've released a couple of weeks ago when we said seven. That's going to be the next ADC target that we're adding in the bag with Colune, Beyond, SAC, TMT. So they're going to continue to look at combining O01 across their portfolio of ADCs, and that's really the belief in combination therapy going forward. We're executing our own studies here in the U.S., Europe, and South Korea and other geographies as fast as they are, and that's been impressive to them. And so we have a trust amongst each other and a real belief and commitment to really looking at creative ways to further our relationship and explore how we can create meaningful clinical data as quickly as we can. And, you know, like we said, by the middle of next year, we'll have over 2,000 patients dozed across the entire portfolio. We'll have multiple ADC combos in study. We'll have the SAC TMT01 data coming sometime in next year. We'll have our own studies coming with standard care chemo combos across multiple chemo agents. There's eight cohorts they're running, 20 to 40 patients per cohort. And so we're just setting ourselves up with our partnership with Colune to generate a lot of data and really understand how valuable O01 can be as a backbone therapy. Maybe you want to comment a little bit on the SAC-TMT piece?

Jonathan McNeill, COO

Yeah, and on the SAC-TMT piece, so we have three ongoing Phase II studies with Colune in China combining SAC-TMT with CRO-1 across lung cancer and multiple other advanced solid tumors, and that includes hundreds of patients' worth of data. This is the first of multiple ADC combination studies that we're going to pursue with Colun, and if you look at their declared clinical portfolio, they have a B7H3 ADC, Claudin ADC, Nectin ADC, all of which are eligible for combination with O1, in addition to the integrin beta-6 topo ADC, which we have a license to outside of greater China. So we're very excited to generate that data, and to a cautious question around optimizing dose, our base case scenario is that we will dose Q3 a week or similar to Ivanesimab. That being said, as we generate data across all the studies we're doing with Calhoun, all of our internal studies, there, of course, will be an opportunity to explore whether alternative dosing regimens make sense. But to date, we haven't seen a need to explore that as of yet. But it's an optionality that we have. And it speaks to optionality we have. When we think about dosing formats, another optionality we have is that from a manufacturability perspective, we modified CRO1 to have enhanced solubility. That should allow us to potentially pursue sub-Q dosing from a life cycle management perspective. So that is something that we plan to explore, not in these initial studies. But I bring that up in the case of that we are thinking on a go-forward basis around our phase three studies and then potential future commercialization, how we can have advantages there as well.

Akash Tawari, Analyst — Jefferies

You know, it's interesting, and I was just hosting an AI panel, and I brought up this topic of how assets are becoming commoditized. So then the differentiation really becomes clinical development, access to data, and speed. You know, when you think about, you know, I think two years ago, everyone's like, well, there's 25 PD-1 VEGFs in China. Based on our work, I think you would be the only unpartnered company that would have access. By next year, you'll have data in the U.S., you'll have data in China, you'll have data in other populations globally. Let's revisit that kind of question you got back in the day. There's a lot of different PD-1 VEGFs in development. How different is your external discussions now? Because you've been able to generate data across different geographies.

Josh Brown, CEO

Yeah, I'd say it's substantially different. I think, you know, when we first started in March of 2025, we had three key questions. One, how are you going to differentiate yourself between all the other by-specific China? How are you going to catch up to everyone else that's ahead of you? And, you know, the other question was really thinking about... The ability for us to differentiate the molecule, right? And this is a class of drugs. Is this really good? Is Harmony 6 going to hit? Is Harmony 2 going to hit? Do we have a class of drugs here? And so I think, by and large, all three of those questions have been answered substantially. To your point, I think we have now moved ourselves into the leadership pack here of the ability to run clinical stage studies to be the next in line for phase three research studies. We put out a press release set by early 2028, where I'll start the first of our multiple phase three studies. And, you know, our CMO's not here today, but she's been super on point by saying that, you know, it's not where you start, but it's where you finish, right? And she lived that. We've all lived that, but she lived that directly with her Tesoro experience and being the seventh P to one approved with Jen Purley and winning and beating the big Good boys with an individual first line, right? And so that spirit lives with inside of us. So we've been able to catch up quickly, answer the question of how we can compete with those ahead of us. I think outside of lung and colorectal, there's still multiple opportunities for first in class to think about the current PD-1 label and where you can play and replacing the first-gen PD-1s with the second-gen PD-1 VEGF bispecific. So I think we've done that. I think checked that box. I think all the Harmony data out there, again, for positive studies on OS, checks the box as a classic drug. You've seen pharma shift substantially from, again, kind of being on the fence pre-Harmony 6, pre-ASCA, really now kind of all being in, trying to figure out what's their backbone therapy for the next-gen IO. And I think from a perspective of how you're going to compete with the Chinese by specifics, I think Colun's answered that and validated that by choosing us. A Chinese company chose our molecule for very specific reasons to be their partner of choice across their whole portfolio. And so I think we're in a really good spot there. The conversations have shifted dramatically, and I think pharma's commitment to this being a class of drugs and their belief in it has also shifted drastically.

Akash Tawari, Analyst — Jefferies

Hmm. Dramatically post-ASCO.

Josh Brown, CEO

Post-ASCO.

Jonathan McNeill, COO

ASCO. And I'd add ESMO as well, because I think, I mean, there's emerging data in this space. Yeah, I know. And the increasing recognition you see, our strategy from the start was synergistic combination of next-gen I.O. in the context of CRO1 plus ADCs in our portfolio or otherwise. And what I think you've also seen is a shift toward many others starting to execute on that strategy, which has been ours in the beginning. You see in our portfolio, you see in our Colune, but many of the recent deals you've seen are recognizing the importance of combining the PD-1-VEGF with ADCs. And so, again, we welcome that competition. We think it's validation of our strategy, and we seem to think that we have a leadership position, both in ourselves and with our partner Colune, in generating very meaningful clinical data in 27, which will then drive to these Phase III initiations in 2028.

Josh Brown, CEO

But I would just say, Akash, you're spot on with assets are becoming more commoditized. This clinical strategy and execution is how you can truly differentiate, and you've got to bet on yourself, right, and this is not the first time this team has been together to execute and make this effort, and I think where we've come, I mean, this time last year, we hadn't even signed the Clune partnership, if you think about that, right, so we announced that December 4th of last year. Here we are, you know, not even a year later with nine cleared INDs, 2,000 patients on the cusp of being dosed by the middle of next year, three programs in the clinic. We were sitting here last year with no program in the clinic, no club partnerships. So it just shows you how quickly you can work when you're focused and you have the right team.

Akash Tawari, Analyst — Jefferies

Understood. Um, and I remember, uh... What Peter originally called me, and he was thinking about even the company formation, and I was like, you know what, I don't know what you're talking about, Peter. He was so convinced, and it's been a prediction that's aged quite well, having PK similarity, figuring out your right dose is a de-risking step that maybe we don't think about enough on the investor side, but strategics really do care about, right? So, you know, during this conference, we hosted Gilead, and I was talking to Andy. Look at what they've done. They combined with Pumidimig with Trodelphi, right? So they made a pragmatic decision to take a PD-1VGF from another company that already had a partnership with Bristol, but the rate-limiting step to me seemed like they at least had data and identified dose and different indications. That seems to be quite important from a strategic perspective.

Josh Brown, CEO

I mean, look, it's super validating. You've got two major players, and Gilead's a top-ten ecology franchise, and both searching out one needed the backbone, and one's looking for ADCs, right? And so that's the value we have, is that we have the backbone. We engineered and designed it very carefully and thoughtfully to replicate the cooperative pharmacology of Avonestimab for the reasons that you just stated. And so I do think the Q1 data around PK, receptor occupancy, safety tolerability, you know, half-life, all is going to really, really matter, right? And that's why we want to check the box for that in the Q1 setting. But, you know, owning the backbone, having the backbone is a better place to be than trying to find the ADCs because it can combine with many, many players. And so I often say this, but, you know, we are open for business. We are open for business to partner and look for other ADCs to combine with O-1, just like the deal of Treveldi and triple negative rest. It's a great, great, great idea.

Jonathan McNeill, COO

And on that question of finding dose, I mean, that is the purpose of all the data regenerating in 2027 across monotherapy, across standard care chemotherapy, across ADC combinations, because with that data, anyone who is a potential partner can feel confident of what they'll see if they combine their own assets with O-1.

Akash Tawari, Analyst — Jefferies

And maybe just to push on this a little more, when you think about external discussions, because I sense this pragmatism, like Merck was looking at some of the emerging data, not just with the Lenovo compound, but even your compound, when they're thinking about making a class decision. Do you feel like when you have external partnership discussions, people are leveraging the PKPD data from Ivanesimab and applying it to how... Oh, well, one will perform at different indications, right? Like, do you benefit from that kind of leverage and the work that Summit's already done because of how your molecule is designed?

Josh Brown, CEO

Yeah, I mean, maybe I'll start and you can finish off. But, I mean, I can tell you, not just for strategics, but even the FDA, we started at a dose 10x higher where Ivone Smep started right out of the gate. It's also what allowed us to move so quickly in the clinic. So we started at three mix per kg in our phase one study. And so we're benefiting even there from having designed this molecule the way that we designed it. But on the strategic side, I'd say yes, people are focused on that and definitely interested.

Jonathan McNeill, COO

Yeah, I mean, and the short answer is yes, now there is leveraging of the data. But over time, as we generate our own data, which is already happening, and we'll have the chance to share that publicly next year, it becomes less and less about standing on those and more about standing on our own to be with our own data. And we're excited for that next year.

Akash Tawari, Analyst — Jefferies

Good. Um, now, um... When we kind of take a step back, and I'm going to make you pick some favorite children here on the ADC front. You know, like we're all at ESMO, B6A, okay, maybe it works a little better in less pretreated patients, but again, you're going, I didn't walk away with a clear signal about where to take B6A versus another highly expressed target like Trope 2. And I'm sure your team is having these discussions as well. So when you think about your ADC portfolio and the targets you've picked and the design, Are there any assets that, as data sets have emerged over the last couple of years, you're getting increasingly excited about and you feel like there's a clear point-and-shoot product differentiation pitch that investors should be paying attention to?

Jonathan McNeill, COO

So I won't say it's our favorite child, but I think the differentiation story on our integrin beta-6 ADC is fairly clear, which is Pfizer has done a great job explaining the market opportunity for an effective integrin beta-6 ADC. It's just the data has not played out as of yet. Our ADC that we in-licensed from Colune, leveraging the exact same platform that was used to make SAC-TMT is differentiated from the S-V asset by its antibody. We have the antibody that's optimized for internalization. It's FC silent by the linker. We're using a proprietary link instead of the VALS-SIT linker that Colune that Pfizer using from the C-Gen historical technology. And of course, the payload. We're using a toposomerase payload. That's an enhanced version of that used in SAC-TMT versus the MMAE So we think that there's a very clear differentiation there around the integrin-beta-6 ADC design, and when you look at ADCs, you can't select one element of it. It is all the pieces have to come together, and we've seen that in the Trope 2 ADC space, of course, and I think that there's an opportunity for us to be a leader in the integrin-beta-6 ADC space, both as monotherapy and that data will be coming in Q1-27, but then combining it with O1 as well. So I think that's a very clear differentiation story. We need the clinical data to bear that out, and that's the data we're generating right But from a design perspective, I think there's a very clear differentiation, and, you know, we respect all the work Pfizer's done, elucidating the integrin-beta-6 space, but our learnings from their data are somewhat limited because of these designs of the molecules having such differentiation.

Josh Brown, CEO

Yeah, and I would say, you know, look, Pfizer's very much still committed to the target. They have a second-gen asset with a topo payload, same antibody, but different payload and linker, And so they're still very much committed. They're not walking away from the target. I will also say that the pharma, by and large, we get a lot of questions about an interest in our integrated benefits, Topo ADC-003. And I think, you know, history, again, is littered with examples of, like, Mursana and Tubulus, where first-gen approach to the target didn't work, and then Tubulus had a great outcome. So I think it's all about the design of the molecule, how you target and how you build it. And so we feel we're differentiated across all three assets, as Jonathan has walked you through. And I think we're very excited about that asset.

Akash Tawari, Analyst — Jefferies

Understood. And maybe just a last point on with the ADC. You know, I'm seeing our European pharma analyst, Mike. We struggle with this question all the time, which is all these topo ADCs are probably going to move into a dominant position, front line, second line, for all these solid tumor indications. And this question of target-mediated resistance, you know, chemo-mediated resistance is becoming an increasingly problematic issue. Calhoun's thought about this, right? All right, so... Talk a bit about lung and, you know, the critique you'll say, which is, well, SAC TMT is going to go front line. Everyone's going to be on a topo payload. Is there something about maybe your chemo, the fact that it's a different target that actually would allow you to uniquely overcome target mediated resistance that maybe investors don't fully appreciate?

Jonathan McNeill, COO

Yeah, I think. First, we think that Integrum Beta 6 ADC will have a role not just after SAC TMT. That's something that we can explore, but we think there will be space, even though Merck and others are exploring a very broad clinical development plan with SAC TMT. And as you alluded to, we're very excited to generate data with SAC TMT in 01, and we're uniquely positioned to do so in this space. I would say, you know, stay tuned around how we can think about that topo-after-topo question. It may be addressed via the Integrum Beta 6 ADC, but as Josh said, we're open for business, and we're always evaluating And I talked about just the two columns of our business pillars, if you will, with the strategies around IO and the next-gen IO backbone, as well as the ADCs and other modalities that we can use to combine.

Josh Brown, CEO

I think that we're very much committed to thinking about what's even beyond the bi-specific space and the IO sleeve of our business, as well as what's next coming from the ADCs and what is Topo after Topo? How big of a deal is that? How do we think about ADCs that go beyond Topo and what's next and other modalities, RAS inhibitors, et cetera, things that you could put on and combine with O-1. So we're focused on that, and we're going to be super aggressive about thinking about other ideas and other modalities to combine with O-1, and then what's next in that sleeve of our business as well.

Akash Tawari, Analyst — Jefferies

We are over time. Actually, you said something quite provocative, which is... Again, I don't think people think about, you talk to kind of these lung docs, they're like, look, there's target oncology, then there's, you know, Pembro chemo, and then whatever will replace it. But the sense is the ADC is the addition in the unselected population. This is now, I picked this up at ESMO as well. There's an increasing, I think, mentality that actually ADCs will be a critical part of targeted oncology as well. What's your view on that, and are there any data sets your team's generating? I know, I think Maloon's generating data with SAC team and OC right now. Is your team looking at maybe targeted oncology treatments in lung and other indications?

Jonathan McNeill, COO

Short answer is yes. Yeah, I mean, I think we continue to have a broad view, and again, we think NextGenIO agents combined with targeted oncology is the future. We are starting with ADCs. We think ADCs are an important element of that, but we are certainly not limited to that as we think about the scope of what we can do in the future.

Akash Tawari, Analyst — Jefferies

Understood. We're over time. I really do appreciate everyone's patience. Thank you, guys. Appreciate you. And my lateness, but hey, thank you.